Limits...
A Macroporous Bioreactor Super Activated by the Recombinant Human Transforming Growth Factor-β(3).

Ripamonti U, Teare J, Ferretti C - Front Physiol (2012)

Bottom Line: Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone.On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs.The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

View Article: PubMed Central - PubMed

Affiliation: Bone Research Unit, Faculty of Health Sciences, School of Physiology, Medical Research Council/University of the Witwatersrand Johannesburg, South Africa.

ABSTRACT
Macroporous single phase hydroxyapatite (HA) and biphasic HA/β-tricalcium phosphate with 33% post-sinter hydroxyapatite (HA/β-TCP) were combined with 25 or 125 μg recombinant human transforming growth factor-β3 (hTGF-β(3)) to engineer a super activated bioreactor implanted in orthotopic calvarial and heterotopic rectus abdominis muscle sites and harvested on day 30 and 90. Coral-derived calcium carbonate fully converted (100%) and partially converted to 5 and 13% hydroxyapatite/calcium carbonate (5 and 13% HA/CC) pre-loaded with 125 and 250 μg hTGF-β(3), and 1:5 and 5:1 binary applications of hTGF-β(3): hOP-1 by weight, were implanted in the rectus abdominis and harvested on day 20 and 30, respectively, to monitor spatial/temporal morphogenesis by high doses of hTGF-β(3). Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone. On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs. The induction of bone formation is controlled by the implanted ratio of the recombinant morphogens, i.e., the 1:5 hTGF-β(3):hOP-1 ratio by weight was greater than the inverse ratio. The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

No MeSH data available.


Related in: MedlinePlus

Distribution of newly formed bone, fibrovascular tissue and residual scaffold material in heterotopic implants, 30 days after implantation with 25 and 125 μg hTGF-β3, in biphasic HA/β-TCP rods and disks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3369251&req=5

Figure 9: Distribution of newly formed bone, fibrovascular tissue and residual scaffold material in heterotopic implants, 30 days after implantation with 25 and 125 μg hTGF-β3, in biphasic HA/β-TCP rods and disks.

Mentions: On day 30, 25 and 125 μg hTGF-β3-treated macroporous constructs showed prominent vascularization throughout the specimens. Macroporous rods loaded with 125 μg hTGF-β3 resulted in greater bone formation (19.61 ± 5.44%) when compared with the disk-shaped implants (7.96 ± 6.39%; Figure 9). Islands of chondrogenesis were seen along the outer rim of the implanted constructs, extending into the porous spaces (not shown). On day 90, newly formed bone was prominently seen surrounding the hTGF-β3-treated matrices extending into the macroporous spaces of both rods and disks. Of note, bone formed predominantly at the periphery of the implanted scaffolds, with minimal bone if any in the center of the pre-loaded constructs (Figure 10). Central macroporous spaces showed lack of bone formation with fibrovascular invasion and multinucleated cells attached to the surface concavities. When evaluated within the macroporous spaces, 125 μg hTGF-β3 resulted in less bone formation (rods: 27.49 ± 1.07%; disks: 25.00 ± 1.00%) when compared to 25 μg hTGF-β3 (rods: 35.92 ± 2.42%; disks: 32.25 ± 2.25%; Figure 11).


A Macroporous Bioreactor Super Activated by the Recombinant Human Transforming Growth Factor-β(3).

Ripamonti U, Teare J, Ferretti C - Front Physiol (2012)

Distribution of newly formed bone, fibrovascular tissue and residual scaffold material in heterotopic implants, 30 days after implantation with 25 and 125 μg hTGF-β3, in biphasic HA/β-TCP rods and disks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3369251&req=5

Figure 9: Distribution of newly formed bone, fibrovascular tissue and residual scaffold material in heterotopic implants, 30 days after implantation with 25 and 125 μg hTGF-β3, in biphasic HA/β-TCP rods and disks.
Mentions: On day 30, 25 and 125 μg hTGF-β3-treated macroporous constructs showed prominent vascularization throughout the specimens. Macroporous rods loaded with 125 μg hTGF-β3 resulted in greater bone formation (19.61 ± 5.44%) when compared with the disk-shaped implants (7.96 ± 6.39%; Figure 9). Islands of chondrogenesis were seen along the outer rim of the implanted constructs, extending into the porous spaces (not shown). On day 90, newly formed bone was prominently seen surrounding the hTGF-β3-treated matrices extending into the macroporous spaces of both rods and disks. Of note, bone formed predominantly at the periphery of the implanted scaffolds, with minimal bone if any in the center of the pre-loaded constructs (Figure 10). Central macroporous spaces showed lack of bone formation with fibrovascular invasion and multinucleated cells attached to the surface concavities. When evaluated within the macroporous spaces, 125 μg hTGF-β3 resulted in less bone formation (rods: 27.49 ± 1.07%; disks: 25.00 ± 1.00%) when compared to 25 μg hTGF-β3 (rods: 35.92 ± 2.42%; disks: 32.25 ± 2.25%; Figure 11).

Bottom Line: Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone.On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs.The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

View Article: PubMed Central - PubMed

Affiliation: Bone Research Unit, Faculty of Health Sciences, School of Physiology, Medical Research Council/University of the Witwatersrand Johannesburg, South Africa.

ABSTRACT
Macroporous single phase hydroxyapatite (HA) and biphasic HA/β-tricalcium phosphate with 33% post-sinter hydroxyapatite (HA/β-TCP) were combined with 25 or 125 μg recombinant human transforming growth factor-β3 (hTGF-β(3)) to engineer a super activated bioreactor implanted in orthotopic calvarial and heterotopic rectus abdominis muscle sites and harvested on day 30 and 90. Coral-derived calcium carbonate fully converted (100%) and partially converted to 5 and 13% hydroxyapatite/calcium carbonate (5 and 13% HA/CC) pre-loaded with 125 and 250 μg hTGF-β(3), and 1:5 and 5:1 binary applications of hTGF-β(3): hOP-1 by weight, were implanted in the rectus abdominis and harvested on day 20 and 30, respectively, to monitor spatial/temporal morphogenesis by high doses of hTGF-β(3). Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone. On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs. The induction of bone formation is controlled by the implanted ratio of the recombinant morphogens, i.e., the 1:5 hTGF-β(3):hOP-1 ratio by weight was greater than the inverse ratio. The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

No MeSH data available.


Related in: MedlinePlus